Apyx Medical Corporation (APYX)
NASDAQ: APYX · IEX Real-Time Price · USD
1.320
0.00 (0.00%)
Apr 24, 2024, 2:51 PM EDT - Market open
Apyx Medical Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Apyx Medical stock have an average target of 6.17, with a low estimate of 4.50 and a high estimate of 9.00. The average target predicts an increase of 367.42% from the current stock price of 1.32.
Analyst Consensus: Buy
* Price targets were last updated on Nov 10, 2023.
Analyst Ratings
The average analyst rating for Apyx Medical stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Maintains $8 → $5 | Buy | Maintains | $8 → $5 | +278.79% | Nov 10, 2023 |
| Piper Sandler | Piper Sandler | Buy Maintains $4 → $4.5 | Buy | Maintains | $4 → $4.5 | +240.91% | Aug 11, 2023 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $8 | Buy | Initiates | $8 | +506.06% | Jul 14, 2023 |
| Lake Street | Lake Street | Strong Buy Maintains $6 → $9 | Strong Buy | Maintains | $6 → $9 | +581.82% | Jun 15, 2023 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 24, 2023 |
Financial Forecast
Revenue This Year
50.94M
from 52.35M
Decreased by -2.70%
Revenue Next Year
55.61M
from 50.94M
Increased by 9.19%
EPS This Year
-0.79
from -0.54
EPS Next Year
-0.71
from -0.79
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 52.6M | 60.6M | 90.4M | 125.9M | 170.0M |
| Avg | 50.9M | 55.6M | 72.3M | 111.2M | 139.6M |
| Low | 48.7M | 52.4M | 57.7M | 96.0M | 109.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.5% | 18.9% | 62.5% | 74.1% | 53.0% |
| Avg | -2.7% | 9.2% | 30.0% | 53.7% | 25.6% |
| Low | -7.0% | 2.9% | 3.7% | 32.8% | -1.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.76 | -0.61 | -0.42 | 0.05 | 0.30 |
| Avg | -0.79 | -0.71 | -0.49 | 0.05 | 0.30 |
| Low | -0.89 | -0.87 | -0.56 | 0.05 | 0.28 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 497.1% |
| Avg | - | - | - | - | 480.0% |
| Low | - | - | - | - | 457.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.